Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Dermata Therapeutics, Inc. - Common Stock (NQ:DRMA)

2.900 +0.130 (+4.69%)
Streaming Delayed Price Updated: 4:00 PM EST, Dec 9, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Dermata Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >
News headline image
Dermata Therapeutics Announces Exercise of Warrants for $6.2 Million in Gross Proceeds Priced At-the-Market Under Nasdaq Rules
Via ACCESS Newswire
News headline image
Which stocks are gapping on Thursday? ↗
The market is buzzing with gapping stocks on Thursday. Let's uncover which stocks are experiencing notable gaps during today's session. 
Via Chartmill
News headline image
Gold Gains Over 1%; TD SYNNEX Shares Plunge After Downbeat Results ↗
 
Via Benzinga
News headline image
Dermata to Present on BioPub on January 31, 2025
Via ACCESS Newswire
News headline image
Dermata Receives Approval from FDA for the Proprietary Name Xyngari(TM)
Via ACCESSWIRE
News headline image
Dermata Receives Notice of Allowance for New U.S. Patent for DMT310 for the Treatment of Acne
Via ACCESSWIRE
News headline image
Dermata Completes Enrollment in First Pivotal DMT310 Phase 3 STAR-1 Clinical Trial for Acne
Via ACCESSWIRE
News headline image
Top movers in Thursday's pre-market session ↗
Before the opening bell on Thursday, let's take a glimpse of the US markets and explore the top gainers and losers in today's pre-market session. 
Via Chartmill
News headline image
Nano-Cap Dermata Therapeutics Unveils Positive Data From Once Weekly Drug Study For Acne ↗
Dermata's Xyngari showed significant acne improvement in Phase 3 results. A second pivotal trial is set for the second half of 2025. 
Via Benzinga
News headline image
Nasdaq Down Over 100 Points; US Initial Jobless Claims Fall ↗
 
Via Benzinga
News headline image
Dermata Therapeutics Provides Corporate Update and Reports Year End 2024 Financial Results
Via ACCESS Newswire
News headline image
Dermata Therapeutics Provides Corporate Update and Reports Third Quarter 2024 Financial Results
Via ACCESSWIRE
News headline image
Peering Into Dermata Therapeutics's Recent Short Interest ↗
 
Via Benzinga
News headline image
Dermata Therapeutics Provides Corporate Update and Reports Second Quarter 2024 Financial Results
Via ACCESSWIRE
News headline image
Dermata Receives Notice of Acceptance of Australian Patent Application for Topical Botulinum Toxin Treatment for Hyperhidrosis
Via ACCESS Newswire
News headline image
Dermata Therapeutics Announces $2.55 Million Private Placement Priced At-The-Market Under Nasdaq Rules
Via ACCESS Newswire
News headline image
Dermata and Revance Enter Clinical Trial Collaboration Agreement for the Topical Application of Xyngari(TM) with Daxxify(R)
Via ACCESS Newswire
News headline image
Life Sciences Investor Forum: Presentations Now Available for Online Viewing
Company Executives Share Vision and Answer Questions Live at VirtualInvestorConferences.com 
From Virtual Investor Conferences
Via GlobeNewswire
News headline image
Life Sciences Investor Forum Agenda Announced for November 14th
Company Executives Share Vision and Answer Questions Live at VirtualInvestorConferences.com 
From Virtual Investor Conferences
Via GlobeNewswire
News headline image
Dermata Therapeutics to Present at the Life Sciences Investor Forum on Thursday, November 14, 2024
– Dermata Therapeutics invites individual and institutional investors, as well as advisors and analysts, to attend online at VirtualInvestorConferences.com – 
From Virtual Investor Conferences
Via GlobeNewswire
News headline image
Dermata Therapeutics to Participate in the 2024 Maxim Healthcare Virtual Summit on Tuesday, October 15, 2024
Via ACCESSWIRE
News headline image
Dermata Therapeutics Announces Closing of $3.5 Million Private Placement Priced At-The-Market Under Nasdaq Rules
Via ACCESSWIRE
News headline image
Why Intel Shares Are Trading Higher By Around 7%; Here Are 20 Stocks Moving Premarket ↗
 
Via Benzinga
News headline image
Dermata Therapeutics Announces $3.5 Million Private Placement Priced At-The-Market Under Nasdaq Rules
Via ACCESSWIRE
News headline image
Dow Jumps Over 200 Points; NY Empire State Manufacturing Index Increases In September ↗
 
Via Benzinga
Topics Stocks
News headline image
Why Exicure Shares Are Trading Higher By Over 49%; Here Are 20 Stocks Moving Premarket ↗
 
Via Benzinga
News headline image
Dermata Therapeutics Announces Participation at the H.C. Wainwright 26th Annual Global Investment Conference September 9-11, 2024
Via ACCESSWIRE
News headline image
Texas Instruments To Rally Around 16%? Here Are 10 Top Analyst Forecasts For Wednesday ↗
 
Via Benzinga
News headline image
7 F-Rated Growth Stocks to Avoid Like the Plague in August 2024 ↗
If your growth stocks have stopped growing then you may be holding on to F-rated growth stocks. It's time to sell. 
Via InvestorPlace
News headline image
DRMA Stock Earnings: Dermata Therapeutics Misses EPS for Q2 2024 ↗
DRMA stock results show that Dermata Therapeutics missed analyst estimates for earnings per share the second quarter of 2024. 
Via InvestorPlace
< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.